U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07297199) titled 'A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55' on Dec. 09.

Brief Summary: In this study, researchers will learn more about BIIB141, also known as omaveloxolone or SKYCLARYS(R). This drug has been approved, or made available for doctors to prescribe, for people with Friedrich's Ataxia (FA) who are at least 16 years old. Currently, BIIB141 is taken by mouth as capsules or capsule contents sprinkled over applesauce. But, there may be some people who have trouble swallowing capsules. In this study, ...